← Back to all trials
Completed
NCT05864105
PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE2
Enrollment: 35
Sponsor: Biotheus Inc.
Location: Anhui Provincial Hospital Hefei Anhui
Summary
This is a multicenter, single-arm, open-label phase II study to evaluate the efficacy and safety of PM8002 in combination with chemotherapy in the first-line treatment of subjects with inoperable HCC.
Eligibility Criteria
Inclusion Criteria:
1. Voluntary participation in clinical study; fully understand the study and sign informed consent voluntarily; willing to follow and able to complete all test procedures;
2. Male or female aged \>= 18 years;
3. HCC diagnosed by pathology or clinical;
4. BCLC stage C or B (unresectable or/and not suitable for local therapy);
5. Child-Pugh score \
Source: ClinicalTrials.gov (NCT05864105). StuddyBuddy aggregates publicly available trial information.
